S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.55 (-1.02%)
MSFT   419.42 (-0.48%)
META   487.45 (-1.30%)
GOOGL   150.88 (+0.01%)
AMZN   179.71 (-0.07%)
TSLA   178.57 (-0.70%)
NVDA   892.52 (-1.11%)
NIO   4.69 (+0.43%)
AMD   179.45 (-0.08%)
BABA   72.16 (+0.80%)
T   17.64 (+0.51%)
F   13.16 (+0.77%)
MU   119.05 (-0.08%)
CGC   9.07 (-5.03%)
GE   177.49 (-1.46%)
DIS   121.30 (+0.26%)
AMC   3.80 (-12.44%)
PFE   27.82 (+0.14%)
PYPL   66.81 (+0.36%)
XOM   115.75 (+0.68%)
NASDAQ:NOTV

Inotiv (NOTV) Stock Price, News & Analysis

$10.66
+0.01 (+0.09%)
(As of 09:38 AM ET)
Today's Range
$10.63
$10.76
50-Day Range
$3.27
$11.04
52-Week Range
$1.61
$11.42
Volume
7,107 shs
Average Volume
377,815 shs
Market Capitalization
$274.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.17

Inotiv MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.3% Upside
$15.17 Price Target
Short Interest
Healthy
4.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Inotiv in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
23.08%
From $1.04 to $1.28 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.69 out of 5 stars

Medical Sector

419th out of 939 stocks

Diagnostics & Research Industry

1st out of 2 stocks

NOTV stock logo

About Inotiv Stock (NASDAQ:NOTV)

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

NOTV Stock Price History

NOTV Stock News Headlines

Craig-Hallum Keeps Their Buy Rating on Inotiv (NOTV)
NOTV May 2024 10.000 call
Warning: this could blow your mind
Buckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…
NOTV Apr 2024 17.500 call
NOTV Apr 2024 2.500 call
Inotiv Inc NOTV
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
3 Overlooked Stocks with Potential for 500% Growth by 2025
Inotiv Stock (NASDAQ:NOTV) Insider Trades
Are Investors Undervaluing Inotiv (NOTV) Right Now?
Inotiv First Quarter 2024 Earnings: Beats Expectations
See More Headlines
Receive NOTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inotiv and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/07/2024
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:NOTV
Employees
2,055
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.17
High Stock Price Target
$25.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+42.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-105,140,000.00
Pretax Margin
-6.95%

Debt

Sales & Book Value

Annual Sales
$572.42 million
Cash Flow
$0.42 per share
Book Value
$10.41 per share

Miscellaneous

Free Float
24,295,000
Market Cap
$274.66 million
Optionable
Optionable
Beta
3.13
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Robert W. Leasure Jr. (Age 64)
    President, CEO & Director
    Comp: $2M
  • Ms. Beth A. Taylor CPA (Age 59)
    Senior VP of Finance & CFO
    Comp: $461.16k
  • Dr. John E. Sagartz D.V.M. (Age 58)
    DiplomateACVP, Ph.D., Chief Strategy Officer & Director
    Comp: $438.61k
  • Dr. Peter T. Kissinger (Age 79)
    Founder, Chairman Emeritus & Scientific Advisor
    Comp: $330.12k
  • Mr. Brennan Freeman (Age 37)
    VP of Finance, Principal Accounting Officer & Corporate Controller
  • Ms. Andrea Castetter
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Adrian Hardy Ph.D. (Age 53)
    Executive VP of Global Marketing & Corporate Development
    Comp: $2.74M
  • Mr. Jeffrey Arthur Krupp (Age 53)
    Chief Human Resources Officer
  • Mr. John Gregory Beattie DSA (Age 57)
    Chief Operating Officer of DSA
  • Mr. Michael Garrett M.S. (Age 56)
    Chief Commercial Officer

NOTV Stock Analysis - Frequently Asked Questions

Should I buy or sell Inotiv stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inotiv in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NOTV shares.
View NOTV analyst ratings
or view top-rated stocks.

What is Inotiv's stock price target for 2024?

3 brokers have issued twelve-month target prices for Inotiv's stock. Their NOTV share price targets range from $9.00 to $25.00. On average, they anticipate the company's stock price to reach $15.17 in the next year. This suggests a possible upside of 42.3% from the stock's current price.
View analysts price targets for NOTV
or view top-rated stocks among Wall Street analysts.

How have NOTV shares performed in 2024?

Inotiv's stock was trading at $3.67 on January 1st, 2024. Since then, NOTV stock has increased by 190.5% and is now trading at $10.66.
View the best growth stocks for 2024 here
.

When is Inotiv's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our NOTV earnings forecast
.

How were Inotiv's earnings last quarter?

Inotiv, Inc. (NASDAQ:NOTV) released its quarterly earnings results on Wednesday, February, 7th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.67. The business had revenue of $135.50 million for the quarter, compared to analysts' expectations of $136.26 million. Inotiv had a negative net margin of 5.67% and a negative trailing twelve-month return on equity of 10.99%.

What guidance has Inotiv issued on next quarter's earnings?

Inotiv updated its FY 2024 earnings guidance on Wednesday, February, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.0 million-$590.0 million, compared to the consensus revenue estimate of $578.1 million.

Who are Inotiv's major shareholders?

Inotiv's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.01%), Vanguard Group Inc. (4.01%), Balyasny Asset Management L.P. (3.78%), KPP Advisory Services LLC (0.64%), Wynnefield Capital Inc. (0.58%) and King Luther Capital Management Corp (0.38%). Insiders that own company stock include Gregory Cole Davis, James Harkness, John E Sagartz, John E Sagartz, John Gregory Beattie, Michael Garrett, Philip A Downing, R Matthew Neff, Robert Jr Leasure and William D Pitchford.
View institutional ownership trends
.

How do I buy shares of Inotiv?

Shares of NOTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NOTV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners